[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

@article{Hofman2018177LuPSMA617RT,
  title={[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.},
  author={Michael S Hofman and John A Violet and Rodney J Hicks and Justin Ferdinandus and Sue Ping Thang and Tim J. Akhurst and Amir Iravani and Grace Kong and Aravind S. Ravi Kumar and Declan G. M. Murphy and Peter Eu and Price A. Jackson and Mark Scalzo and Scott Garrick Williams and Shahneen K. Sandhu},
  journal={The Lancet. Oncology},
  year={2018},
  volume={19 6},
  pages={
          825-833
        }
}
BACKGROUND Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177Lu… CONTINUE READING